Conclusion Plant and marine sources of n-3 PUFAs can modify serum leptin and adiponectin levels by increasing adiponectin and decreasing leptin levels in patients with type 2 diabetes .
Due to some limitations in this study , further studies are needed to reach a definitive conclusion about the effect of n-3 PUFAs on the levels of leptin and adiponectin in T2DM
Abstract Aim N-3 PUFAs can potentially influence levels of inflammatory and non-inflammatory adipokines .
Given the contradictory effects of n-3 PUFAs on serum levels of adipokines in type 2 diabetes , we conducted a systematic review and meta- analysis study of r and omized placebo-controlled clinical trials that examined the effects of n-3 PUFAs on serum levels of leptin and adiponectin in patients with type 2 diabetes .
Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects
Objectives —Fish oil rich in n-3 polyunsaturated fatty acids ( PUFAs ) or n-3 PUFAs have been shown to reduce the incidence of coronary heart disease . Here we investigated the effect of highly purified eicosapentaenoic acid ( EPA ) on production of adiponectin , the only established antiatherogenic and antiinflammatory adipocytokine , in rodent models of obesity and human obese subjects . Methods and Results —We demonstrated that EPA increases adiponectin secretion in genetically obese ob/ob mice and high-fat diet – induced obese mice . In the in vitro coculture of adipocytes and macrophages , EPA reversed the coculture-induced decrease in adiponectin secretion at least in part through downregulation of tumor necrosis factor-&agr ; in macrophages . We also showed significant increase in plasma adiponectin concentrations in human obese subjects after a 3-month treatment with EPA ( 1.8 g daily ) . Multivariate regression analysis revealed that EPA treatment is the only independent determinant of plasma adiponectin concentrations . Conclusion —This study demonstrates that EPA increases adiponectin secretion in rodent models of obesity and human obese subjects , possibly through the improvement of the inflammatory changes in obese adipose tissue . Because EPA has reduced the risk of major coronary events in a large-scale , prospect i ve , r and omized clinical trial , this study provides important insight into its therapeutic implication in obesity-related metabolic sequelae
Conclusion Plant and marine sources of n-3 PUFAs can modify serum leptin and adiponectin levels by increasing adiponectin and decreasing leptin levels in patients with type 2 diabetes .
Due to some limitations in this study , further studies are needed to reach a definitive conclusion about the effect of n-3 PUFAs on the levels of leptin and adiponectin in T2DM
Abstract Aim N-3 PUFAs can potentially influence levels of inflammatory and non-inflammatory adipokines .
Given the contradictory effects of n-3 PUFAs on serum levels of adipokines in type 2 diabetes , we conducted a systematic review and meta- analysis study of r and omized placebo-controlled clinical trials that examined the effects of n-3 PUFAs on serum levels of leptin and adiponectin in patients with type 2 diabetes .